- Home
- GNPX vs LDWY Comparison
GNPX vs LDWY Comparison
Compare GNPX & LDWY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GNPX | LDWY |
|---|---|---|
| Founded | 2009 | 1990 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Advertising |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.4M | 6.2M |
| IPO Year | 2018 | 1991 |
Fundamental Metrics
Financial Performance| Metric | GNPX | LDWY |
|---|---|---|
| Price | $2.32 | $4.35 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 1.1M | 86.9K |
| Earning Date | 11-14-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.70 |
| Revenue | N/A | ★ $69,769,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $6.13 |
| Revenue Growth | N/A | ★ 121.91 |
| 52 Week Low | $1.71 | $3.11 |
| 52 Week High | $55.00 | $6.19 |
Technical Indicators
Market Signals| Indicator | GNPX | LDWY |
|---|---|---|
| Relative Strength Index (RSI) | 45.18 | 61.58 |
| Support Level | $2.63 | $3.52 |
| Resistance Level | $3.04 | $4.83 |
| Average True Range (ATR) | 0.43 | 0.42 |
| MACD | 0.04 | 0.08 |
| Stochastic Oscillator | 31.28 | 63.64 |
Price Performance
Historical ComparisonAbout GNPX Genprex Inc.
Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex's oncology program utilizes its systemic, non-viral Oncoprex Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's product candidate, Reqorsa Immunogene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for NSCLC and SCLC.
About LDWY Lendway Inc. (DE)
Lendway Inc is a specialty agricultural and finance company focused on making and managing its ag investments in the United States and internationally. The company operates in industries: Specialty Ag, consisting of the Bloomia business.